BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
See tonight’s solar storm unfold across the world - 221 Incredibly Entertaining Contemplations To Observe Consistently
- 3Alleged Huione Group Money Laundering Boss Extradited to China
- 4Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
- 5'Senseless violence' erupts at Christmas tree lighting; 4 injured
- The Best Computer games for Multiplayer Fun
- Former biotech CEO sued over COVID vaccine alleged insider trading
- Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- Uranus's small moons are dark, red, and water-poor
- Limited Rain Chances in Brazil Boost Coffee Prices
- Allow Innovative Progressions To have a Tremendous Effect
